Market Overview

LOXO ONCOLOGY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout


Rigrodsky & Long, P.A.:

  • Do you own shares of Loxo Oncology, Inc. (NASDAQ GM: LOXO)?
  • Did you purchase any of your shares prior to January 7, 2019?
  • Do you think the proposed buyout is fair?
  • Do you want to discuss your rights?

& Long, P.A.
announces that it is investigating potential legal
claims against the board of directors of Loxo Oncology, Inc. ("Loxo
Oncology" or the "Company") (NASDAQ GM: LOXO)
regarding possible breaches of fiduciary duties and other violations of
law related to the Company's entry into an agreement to be acquired by
Eli Lilly and Company ("Eli Lilly") (NYSE: LLY)
in a transaction valued at approximately $8.0 billion. Under the terms
of the agreement, shareholders of Loxo Oncology will receive $235.00 in
cash for each share of Loxo Oncology common stock.

If you own common stock of Loxo Oncolgy and purchased any shares before
January 7, 2019, if you would like to learn more about this
investigation, or if you have any questions concerning this announcement
or your rights or interests, please contact Seth D. Rigrodsky or Gina M.
Serra toll-free at (888) 969-4242, by e-mail at,
or at

& Long, P.A.
, with offices in Delaware, New York, and
California, has recovered hundreds of millions of dollars on behalf of
investors and achieved substantial corporate governance reforms in
numerous cases nationwide, including federal
securities fraud actions, shareholder class actions, and shareholder
derivative actions

Attorney advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!